SEP 0 4 2003 %

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Giorgio ATTARDO et al

Serial No.: 09/976,249

Group Art Unit: 1654

Filed: October 15, 2001

Examiner: M. V. Spivack

For: Dioxolane Analogs For Improved Inter-Cellular Delivery

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Mail Stop DD

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

			.R. § 1.97(b), no fee or statement is required for filing this information tement is filed:				
			three months of the filing date of a national application other than a CPA § 1.53(d);				
[within three months of the actual filing date of the national phase of a PC application; OR					
		before the mailing of a first substantive office action (including after filing of a RCE).					
\boxtimes	Under specifi	37 C.F. led in 3	R. § 1.97(c), this information disclosure statement is filed after the periods 7 C.F.R. § 1.97(b), but before the mailing date of:				
		\boxtimes	a final rejection under 37 C.F.R. 1.113;				
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR				
			a notice of allowance under 37 C.F.R. § 1.311; and				
			1				

DOCKET NO.: PHARMA-123

09/05/2003 JBALINAN 00000108 09976249

01 FC:1806

	i	is accor	npanied by:
	ĺ		the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
	[\boxtimes	a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
	Under 3 date of	7 C.F.I the foll	R. § 1.97(d), this information disclosure statement is filed after the mailing owing actions which have not been withdrawn:
			a final action under 37 C.F.R. § 1.113;
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
			a notice of allowance under 37 C.F.R. § 1.311;
	AND is	s filed o	on or before payment of the issue fee; AND is accompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
State	ments Un	ider 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cite	d Materia	ıls	
		ances	es of materials listed but not attached were cited in benefit (35 U.S.C. § 120) tor application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
		Copic repor	es of materials listed but not attached were cited in an international search t dated
	\boxtimes	Copi	es of the materials listed are attached (except for the foregoing).

<u> Non-English I</u>	Language References
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document
	A = document defining the general state of the art O = non-written disclosure
	P = intercalated document T = document cited to understand the theory or principle underlying the invention
	patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D = cited in the application
	L = cited for another reason & = publication of member of same patent family
	Translation of other relevant information on foreign search report
Additional Ir The f	ollowing are related applications: Serial No. 09/536,459 (allowed) and
its divisional	Serial No. 10/046,289 (pending): Serial No. 10/286,960 (allowed);
Serial No. 10)/104,067 (pending); and Serial No. 10/107,795 (pending).
	Fees Due (If Any):
A ch	eck for \$180.00 covering the fee identified above is attached.
Pleas	se charge to Deposit Account No. 13-3402 \$ for the fee identified above.

DOCKET NO.: PHARMA-123

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Brion P. Heaney, Reg. No. 32,542

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: PHARMA-123

Date: September 4, 2003

BPH:lkt

Sheet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

•	TOWN HAS DEDELMORK	(Reaucuo	STACLUL 1995, NO persone			•
Substitute for form 1449A/PTO				Complete if Known		
Substitute for	or form 1449A/PTO			Application Number	09/976,249	
	SEATION!	חופר	LOSURE	Filing Date	October 15, 2001	
INFOR			DUCANT	First Named Inventor	Giorgio ATTARDO	
STAT	EWENIR	Y AP	PLICANT	Group Art Unit	1654	
		oto oo r	20005597/)	Examiner Name M. V. Meller		
	use as many she	-	4	Attorney Docket Number	PHARMA-123	
Sheet	1 1	of	1	Allomey Booker Hames.		

			U.S. P.	ATENT DOCUMENTS	T	
		U.S. Patent Docu	ment		Date of Publication of Cited Document MM-DD-YYYY	
Examiner	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document		
Initials *	1	6,350,753		Belleau et al	02/26/2002	
	 		i,	W		
	 					
				<u>.</u>		
				8		
			•			
	+		4.3%	• • •		
			·			

				FOREIGI	N PATENT DOCUMENTS		Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Office ³	oreign Patent Docu Number ⁴	ument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Τ°
		1						

		. "		
Examiner Signature	.4		Date Considered	
Signature			MDED	eng Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.